Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00882232 · ClinicalTrials.gov registry record · Phase 1
Cross-linked Hyaluronan Gel Reduces Rectal Toxicity Due to Radiation Therapy for Prostate Cancer
A Phase 1 study, sponsored by Cancer Center of Irvine.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT00882232: Completed Phase 1 study, sponsored by Cancer Center of Irvine.
NCT00882232 is a Phase 1 study that has completed, run by Cancer Center of Irvine. The registered enrollment target is 10 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00882232, a Phase 1 study, has completed, sponsored by Cancer Center of Irvine.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
The primary purpose of this study is to determine if cross-linked hyaluronan gel reduces the dose of radiation delivered to the rectum and the rectal toxicity of radiotherapy for localized prostate cancer.
Interventions
- DEVICE Cross-linked hyaluronan gel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2008-09 |
| Est. Completion | 2009-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00882232
The ClinicalTrials.gov registry entry for NCT00882232 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cancer Center of Irvine, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Cross-linked hyaluronan gel is the first listed.
NCT00882232 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00882232 about?
NCT00882232 is a clinical study titled "Cross-linked Hyaluronan Gel Reduces Rectal Toxicity Due to Radiation Therapy for Prostate Cancer". The primary purpose of this study is to determine if cross-linked hyaluronan gel reduces the dose of radiation delivered to the rectum and the rectal toxicity of radiotherapy for localized prostate cancer.
What is the current status of trial NCT00882232?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2008-09. Estimated completion is 2009-09.
What interventions are being tested in trial NCT00882232?
The interventions under investigation include: Cross-linked hyaluronan gel (DEVICE).
Who is sponsoring clinical trial NCT00882232?
This trial is sponsored by Cancer Center of Irvine, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.